Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer

Lung Cancer ◽  
2001 ◽  
Vol 32 (3) ◽  
pp. 307-312 ◽  
Author(s):  
Hazel R Scott ◽  
Donald C McMillan ◽  
Walter S Watson ◽  
Robert Milroy ◽  
Colin S McArdle
Keyword(s):  
Lung Cancer ◽  
Longitudinal Study ◽  
Energy Expenditure ◽  
Inflammatory Response ◽  
Cell Mass ◽  
Resting Energy Expenditure ◽  
Small Cell ◽  
Body Cell Mass ◽  
Small Cell Lung ◽  
Male Patients

Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients.

1995 ◽  
Vol 13 (10) ◽  
pp. 2600-2605 ◽  
Author(s):  
A J Staal-van den Brekel ◽  
M A Dentener ◽  
A M Schols ◽  
W A Buurman ◽  
E F Wouters
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Energy Expenditure ◽  
Inflammatory Response ◽  
Cancer Patients ◽  
Resting Energy Expenditure ◽  
Small Cell ◽  
Systemic Inflammatory Response ◽  
Small Cell Lung ◽  
Lung Cancer Patients

PURPOSE To determine whether an increased resting energy expenditure (REE) and weight loss in lung cancer patients are related to a systemic inflammatory response. MATERIALS AND METHODS REE was measured by indirect calorimetry using a ventilated hood system. Soluble tumor necrosis factor receptor 55 (sTNF-R55) and sTNF-R75, soluble intercellular adhesion molecule (sICAM)-1, soluble E (sE)-selectin, lipopolysaccharide (LPS)-binding protein (LBP), interleukin (IL)-6, and TNF-alpha were measured using sandwich enzyme-linked immunosorbent assay (ELISA), and C-reactive protein (CRP) was measured by turbidimetry. A cross-sectional study was performed to compare inflammatory mediators between hypermetabolic (REE/Harris Benedict [HB] equation > or = 110%) versus normometabolic (REE/HB < 110%) patients and between patients who lost weight (more than 10% loss of preillness weight) versus those whose weight remained stable. RESULTS Eighty-seven patients with primary non-small-cell lung cancer were consecutively entered onto the study. Mean REE expressed as a percentage of the HB reference values was 118% +/- 12%; 67 patients were considered hypermetabolic. Twenty-six patients had a substantial loss of more than 10% of their preillness weight. Hypermetabolic patients were found to have significantly increased levels of sTNF-R55, sE-selectin, LBP, and CRP compared with normometabolic patients. Weight loss was related with increased levels of the sTNF-Rs, sICAM-1, IL-6, LBP, and CRP. CONCLUSION Hypermetabolism and weight loss are related to the presence of a systemic inflammatory response as reflected by enhanced levels of inflammatory mediators and acute phase proteins in patients with primary non-small-cell lung cancer.

scholarly journals Resting energy expenditure in patients with non-small cell lung cancer

Cancer ◽  
1991 ◽  
Vol 68 (7) ◽  
pp. 1616-1621 ◽  
Author(s):  
E. W. H. M. Fredrix ◽  
E. F. M. Wouters ◽  
P. B. Soeters ◽  
A. C. J. M. Van Der Aalst ◽  
A. D. M. Kester ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Energy Expenditure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Resting Energy Expenditure ◽  
Small Cell ◽  
Small Cell Lung ◽  
Resting Energy

Do patients with nonmetastatic non-small cell lung cancer demonstrate altered resting energy expenditure?

2001 ◽  
Vol 72 (2) ◽  
pp. 348-351 ◽  
Author(s):  
Aminah Jatoi ◽  
Benedict D.T Daly ◽  
Virginia A Hughes ◽  
Gerard E Dallal ◽  
Joseph Kehayias ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Energy Expenditure ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Resting Energy Expenditure ◽  
Small Cell ◽  
Small Cell Lung ◽  
Resting Energy

Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer

2019 ◽  
Vol 75 (4) ◽  
pp. 223-230
Author(s):  
Guillaume Ulmann ◽  
Anne Jouinot ◽  
Camille Tlemsani ◽  
Emmanuel Curis ◽  
Isabelle Kousignian ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Energy Metabolism ◽  
Energy Expenditure ◽  
Small Cell Lung Cancer ◽  
Lean Body Mass ◽  
Cell Lung Cancer ◽  
Resting Energy Expenditure ◽  
Small Cell ◽  
Small Cell Lung ◽  
Impaired Energy Metabolism

Background: Cancer and aging are both frequently associated with malnutrition, a factor of poor prognosis. In adult cancer patients, this may be related in part to impaired energy metabolism, with higher than predicted resting energy expenditure (REE) in about 50% of patients. We hypothesized that frequently impaired energy metabolism in elderly patients could potentiate cancer-associated hypermetabolism, further promoting risk of malnutrition. Objective: To study the hypermetabolic response to cancer in a predominantly aged population and the potential underlying determinants. Methods: This was a cross-sectional exploratory study in patients with non-small-cell lung cancer. REE was measured by indirect calorimetry. Body composition was determined from a single CT scan imaging at L3 level. Endocrine, inflammatory, nutritional and metabolic status were evaluated. Results: Twenty-seven patients, of median age 68 years (range 32–81) completed the study. In this population, mean measured REE was 7.5% higher than calculated REE. Sex and weight accounted for about 51% of REE variations, whereas age accounted only for 4%. However, these parameters did not explain the REE-to-lean body mass (LBM) ratio variations, suggesting that they influenced REE only through their effect on LBM. Among the other parameters evaluated, only the thyroid-stimulating hormone and interleukin-6 plasma levels appeared to have an influence on REE. The study of the consequences of this increase in REE-to-LBM ratio showed a growing inability of patients to meet their energy needs but showed no effect on nutritional markers such as transthyretin. Conclusions: The results of this pilot study suggest that in our population, age was not an important factor of REE. The elevated energy metabolism was associated with patients’ failure to increase their energy intakes sufficiently, which can contribute to the development of cachexia. Clinical Trial: This trial is registered at clinicaltrials.gov under NCT0314.

Sign in / Sign up

Export Citation Format

Share Document